Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

IBS breakthrough? gene study links carb digestion to gut pain

NCT ID NCT05795049

Knowledge-focused Sponsor: Nottingham University Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether genetic differences in digesting carbohydrates cause Irritable Bowel Syndrome (IBS) symptoms like belly pain and bloating. Researchers will compare 2000 people with IBS to healthy controls to find how common these gene variants are. The goal is to better understand why some people react to certain foods and pave the way for personalized diet treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Multicentre study. IBS patients identified through secondary and tertiary care gastroenterological clinics. Asymptomatic adult controls recruited at the same site as respective patients or, for instance, from transfusion clinics, blood donor centres, bowel cancer screening as long as data on the absence of symptoms is documented.

Ages

5 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Patients: * Patients age between 5 and 70 years of age. * Patients with IBS-D or IBS-M as defined by the Rome III criteria. * Previous negative endoscopy with biopsies excluding IBD or microscopic colitis in patients above 50 years old * Negative relevant additional screening or consultation whenever appropriate * Ability to conform to the study protocol Exclusion Criteria for Patients: * Patients with IBS-C or IBS-U according to Rome III criteria * Patients with any condition which, in the opinion of the investigator, makes the patient unsuitable for participation in the study. * Patients on opioids * Patients with concurrent organic gastrointestinal disease (inflammatory bowel disease, celiac disease, cancer), or a major disease such as diabetes, uncontrolled thyroid disease * Patients with a history of bowel surgery (not appendectomy or cholecystectomy) * Concurrent major confounding condition, e.g. alcohol or substance abuse in the last 2 years (clinician's judgement). Inclusion Criteria for healthy controls: * Between 5 and 70 years of age * Absence of Rome III IBS criteria Exclusion Criteria for healthy controls: * Blood relatives of the participating IBS patient are not allowed to participate. * Person with any condition which, in the opinion of the investigator, makes them unsuitable for participation in the study. * Person presenting with a functional or organic GI disorder. * Person presenting with underlying disease that may involve the GI tract (e.g. Parkinson's disease) or be associated with GI symptoms (e.g. anorexia nervosa, major depression).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Irritable bowel syndrome (IBS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congenital sucrase-isomaltase deficiency irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Irritable bowel syndrome (IBS) Sucrase-isomaltase deficiency

Contacts and locations

Locations

  • Nottingham University Hospitals NHS Trust

    Nottingham, NG7 2UH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.